Health care industry
‘Economy class syndrome’ is a medical issue that can happen on flights — no matter where you sit
Experts call it “economy class syndrome” — but it can happen to anyone in any class of an airplane. Deep vein thrombosis, or DVT as it’s known, occurs when blood clots in one or more veins. It can happen at any time, but people who travel on long-haul flights are at a higher risk because […]
Read More
This government-backed startup is growing blood to help fight shortages
Safi employees at work. Courtesy of Safi Biotherapeutics Last month, the American Red Cross declared an emergency blood shortage after its national supply fell by more than 25% in July. One startup’s solution: Lab-grown blood. Shortages can be dire for patients since doctors have to make tough decisions about who needs blood transfusions the most. […]
Read More
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugs
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results. The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental […]
Read More
Eli Lilly names insider Lucas Montarce as new finance chief
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, on March 5, 2021. Mike Segar | Reuters U.S. drugmaker Eli Lilly on Monday said it appointed insider Lucas Montarce as its new chief financial officer, effective immediately. Montarce, who joined Lilly in 2001, has held various finance leadership roles within […]
Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, […]
Read More
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this […]
Read More
Abbott launches its first over-the-counter continuous glucose monitor in the U.S.
A man wearing Abbott’s Lingo biosensor. Courtesy of Abbott Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. Lingo is part of an emerging class of consumer-friendly biosensors that people can use to learn how their bodies respond to food, exercise, sleep and stress. These devices, […]
Read More
GE Healthcare shows signs of life, but a lingering uncertainty keeps us on the sidelines
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. More weakness: There’s been a couple attempts at a rally Wednesday, but stocks are still mostly lower in the second session of September after a rough […]
Read More
We’re taking a nearly 300% profit on a hot drug stock — adhering to an investing rule to live by
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, decreasing its weighting to 2.85% from about 3.13%. Now that we are no longer restricted, we are selling some Eli Lilly shares. We downgraded Lilly […]
Read More